Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

@article{Baldo2015ChimericFP,
  title={Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety},
  author={B. Baldo},
  journal={Drug Safety},
  year={2015},
  volume={38},
  pages={455-479}
}
  • B. Baldo
  • Published 2015
  • Medicine
  • Drug Safety
  • Chimeric fusion proteins, produced by genetic engineering, are currently made up of effector peptides, for example, a ligand-binding portion of a cytokine or growth factor, extracellular domains of lymphocyte antigens, or a toxin linked to a suitable fusion partner. This review covers eight fusion proteins that have received regulatory approval for human therapy: etanercept, belatacept, abatacept, alefacept, rilonacept, romiplostim, aflibercept, and denileukin-diftitox. Important requirements… CONTINUE READING
    Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
    • 164
    • PDF
    A New Approach to Drug Therapy: Fc-Fusion Technology
    • 5
    • PDF
    Variability of intended copies for etanercept (Enbrel®): Data on multiple batches of seven products
    • 13
    Roles of CD48 in regulating immunity and tolerance.
    • 49

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 230 REFERENCES
    Antibody therapeutics:
    • 201
    Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies
    • 136
    • Highly Influential
    Peptibodies: A flexible alternative format to antibodies
    • 67
    Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
    • 149
    • Highly Influential
    Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties
    • 571
    • Highly Influential
    Fc-fusion proteins: new developments and future perspectives
    • 232
    • Highly Influential
    • PDF